Practical experience and model for optimizing RAASi-based therapy in HF
Video navigation menu
- RAASi therapy recommended for HF, CKD and T2DM 00:26
- Barriers leading to suboptimal implementation of RAASi therapy in clinical practice 01:38
- Overcoming the barrier with potassium binders: real-world data 03:11
- Practical guidance for prescribing and monitoring of potassium binders in HF therapy 08:11
- Summary 08:54
During optimization of RAASi therapy, SZC treatment is prescribed to a patient with HFrEF at a dose of 5 mg at alternate days. The serum potassium level of this patient is 5.5 mmol/L during monitoring. What would you consider for this patient?
- A. Adjust the frequency of dose of SZC to once daily.
- B. Increase the dose of SZC to 10 mg alternate days.
- C. Increase the dose of SZC to 10 mg once daily.
- D. Keep patient on the current dose.
- E. Consider down-titration of RAASi-based therapy.
This lecture by Aaron Wong, MD was part of the EBAC-accredited symposium "Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia" at ESC Heart Failure in Prague, Czech Republic.
Aaron Wong, MD is a consultant cardiologist and general physician working at the Princess of Wales Hospital, Bridgend, South Wales, United Kingdom. He is the local heart failure lead, and also works as a local principal investigator.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.